Back to results
US 2003/0225092 A1Published application
Chemical compounds
AssigneeLilly ICOS LLC
InventorsMark W. Orme, Jason Scott Sawyer, Alain Claude-Marie Daugan
Life of this patent
Estimating the term…
Abstract
Compounds of the general structural formula (I) and use of the compounds and salts and solvates thereof, as therapeutic agents. 1
Claims25
A compound having a formula
- 39
- wherein R1 is selected from the group consisting of hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C3-8cycloalkyl, heteroC3-8cycloalkyl, C3-8cycloalkylC1-2alkyl, arylC1-3alkyl, and heteroarylC1-3alkyl;
- R2 is selected from the group consisting of an optionally substituted monocyclic aromatic ring selected from the group consisting of benzene, thiophene, furan, and pyridine, and an optionally substituted bicyclic ring
- 40
- wherein the fused ring A is a 5- or 6-membered ring, saturated or partially or fully unsaturated, and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulfur, and nitrogen;
- R3 is selected from the group consisting of hydrogen and C1-6alkyl,
- or R1 and R3 together represent a 3- or 4-membered alkyl or alkenyl chain component of a 5- or 6-membered ring;
- R4, independently, is selected from the group consisting of
- aryl,
- Het,
- C3-8cycloalkyl,
- YC3-8cycloalkyl (wherein Y is oxygen, sulfur, or NRa),
- C(═O)Ra,
- OC(═O)Ra,
- C(═O)ORa,
- C1-4alkyleneNRaRb,
- C1-4alkyleneHet,
- C1-4alkyleneC(═O)ORa,
- C(═O)NRaSO2Rc,
- C(═O)C1-4alkyleneHet,
- C(═O)NRaRb,
- C(═O)NRaRc,
- C(═O)NRaC1-4alkyleneORb,
- C(═O)NRaC1-4alkyleneHet,
- ORa,
- OC1-4alkyleneC(═O)ORa,
- OC2-4alkyleneNRaRb,
- OC1-4alkyleneHet,
- OC2-4alkyleneORa,
- OC1-4alkyleneNRaC(═O)ORb,
- NRaRb,
- NRaC1-4alkyleneNRaRb,
- NRaC(═O)Rb,
- NRaC(═O)NRaRb,
- N(SO2C1-4alkyl)2,
- NRa(SO2C1-4alkyl),
- nitro (NO2),
- trifluoromethyl,
- trifluoromethoxy,
- cyano (CN),
- SO2NRaRb,
- SO2Ra,
- SRa,
- and OSO2CF3;
- R5 is selected from the group consisting of hydrogen, halogen, and C1-6alkyl;
- or R4 and R5 are taken together with the carbon atoms to which they are attached to form a 5-, 6-, or 7-membered ring, saturated or partially or fully unsaturated, optionally substituted and optionally containing one or two heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen;
- Ra is selected from the group consisting of hydrogen, C1-6alkyl, C3-8cycloalkyl, aryl, arylC1-3-alkyl, C1-3alkylenearyl, and Het;
- Rb is selected from the group consisting of hydrogen, C1-6alkyl, aryl, arylC1-3alkyl, C1-2alkylenearyl, and Het;
- Rc is phenyl or C4-6cycloalkyl, either optionally substituted with one or more substituent selected from the group consisting of halo, C(═O)ORa, and ORa;
- Het is a 5- or 6-membered heterocyclic group, saturated or partially or fully unsaturated, containing at least one heteroatom selected from the group consisting of oxygen, nitrogen, and sulfur, and optionally substituted with C1-4alkyl or C(═O)ORb;
- q is 1, 2, or 3;
- and
- pharmaceutically acceptable salts and hydrates thereof.
50 more elements
A compound selected from the group consisting of
- 44 45 46 47
- and pharmaceutically acceptable salts and solvates thereof.
Dependencies are inferred from the claim text.